<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gilbert syndrome</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gilbert syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gilbert syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jayanta Roy-Chowdhury, MD, MRCP, AGAF, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Namita Roy-Chowdhury, PhD, FAASLD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Xia Wang, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gilbert syndrome (Meulengracht disease, constitutional hepatic dysfunction, and familial nonhemolytic jaundice) is a benign condition characterized by recurrent episodes of jaundice [<a href="#rid1">1,2</a>]. Other than jaundice, patients are typically asymptomatic. The hyperbilirubinemia in patients with Gilbert syndrome is unconjugated. Many patients present as isolated cases but the condition can also run in families. Exacerbations may be triggered by dehydration, fasting, intercurrent disease, menstruation, and overexertion [<a href="#rid3">3</a>]. No treatment is necessary, but it can increase the risk of toxicity from some medications, such as <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>.</p><p>This topic will review the epidemiology, clinical manifestations, diagnosis and management of Gilbert syndrome. Crigler-Najjar syndromes type I and II, neonatal jaundice, and the evaluation of patients with jaundice are discussed separately. (See  <a class="medical medical_review" href="/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis", section on 'Gilbert syndrome'</a> and  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a> and  <a class="medical medical_review" href="/d/html/5020.html" rel="external">"Unconjugated hyperbilirubinemia in neonates: Etiology and pathogenesis"</a> and  <a class="medical medical_review" href="/d/html/3620.html" rel="external">"Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia"</a> and  <a class="medical medical_review" href="/d/html/5947.html" rel="external">"Evaluation of jaundice caused by unconjugated hyperbilirubinemia in children"</a>.)</p><p class="headingAnchor" id="H78565074"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Gilbert syndrome is the most common inherited disorder of bilirubin glucuronidation, with an estimated prevalence of 6 to 14 percent [<a href="#rid4">4-8</a>]. Patients typically present during adolescence when alterations in sex steroid concentrations affect bilirubin metabolism, leading to increased plasma bilirubin concentrations [<a href="#rid9">9</a>]. As a result, it is rarely diagnosed prior to puberty. The disorder is more commonly diagnosed in males, possibly due to a relatively higher level of daily bilirubin production [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H61355743"><span class="h1">GENETICS</span><span class="headingEndMark"> — </span>The genetic defect in patients with Gilbert syndrome involves the promotor region of uridine diphosphoglucuronate-glucuronosyltransferase 1A1 (<em>UGT1A1) </em>gene. Uridine diphosphoglucuronate-glucuronosyltransferases (UGTs) are a family of enzymes that mediate glucuronidation of various endogenous and exogenous compounds. The <em>UGT1A</em> gene that encodes the enzyme UGT1A1 is responsible for the conjugation of bilirubin with glucuronic acid, converting the bilirubin into a water-soluble form that is readily excreted in bile  (<a class="graphic graphic_figure graphicRef52393" href="/d/graphic/52393.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/3622.html" rel="external">"Bilirubin metabolism"</a>.)</p><p>Gilbert syndrome is an autosomal recessive disorder and manifests in people who are homozygous for the variant promoter  (<a class="graphic graphic_table graphicRef80818" href="/d/graphic/80818.html" rel="external">table 1</a>). However, heterozygotes for the Gilbert genotype have higher average plasma bilirubin concentrations compared with those with two wild-type alleles [<a href="#rid10">10</a>]. </p><p>Characterization of the <em>UGT1A1</em> gene locus has permitted an understanding of the molecular defects responsible for Gilbert syndrome. The pathogenic variant responsible for Gilbert syndrome is in the promoter region, upstream to exon 1 of <em>UGT1A1</em> [<a href="#rid10">10</a>]. The normal sequence of the TATAA element within the promoter is A[TA]6TAA. Patients with Gilbert syndrome are homozygous for a longer version of the TATAA sequence, A[TA]7TAA, which causes reduced production of bilirubin-UGT  (<a class="graphic graphic_figure graphicRef73505" href="/d/graphic/73505.html" rel="external">figure 2</a>). This variant is termed <em>UGT1A1*28</em>. The defect in Gilbert syndrome is different from that in the Crigler-Najjar syndromes, in which bilirubin-UGT is either absent or produced in an abnormal form with reduced or no activity. (See  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a>.)</p><p>The longer TATAA element has been found in all subjects with Gilbert syndrome studied in the United States, Europe, and countries of the Middle East and South Asia. However, other factors are probably involved in the expression of the Gilbert phenotype since not all patients who are homozygous for the variant promoter develop hyperbilirubinemia [<a href="#rid10">10</a>]. Furthermore, in the Japanese population, other variants within the coding regions of <em>UGT1A1</em> can cause the Gilbert phenotype [<a href="#rid11">11,12</a>].</p><p>Because of the high frequency of the Gilbert type promoter, some heterozygous carriers of pathogenic variants that cause Crigler-Najjar syndrome type also carry the Gilbert type of TATAA element on their normal allele. Such combined defects can lead to severe hyperbilirubinemia, occasionally causing kernicterus [<a href="#rid13">13,14</a>]. This also explains the frequent finding of intermediate levels of hyperbilirubinemia in the family members of patients with Crigler-Najjar syndrome. (See  <a class="medical medical_review" href="/d/html/3569.html" rel="external">"Crigler-Najjar syndrome"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H78565243"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Patients with Gilbert syndrome typically present with episodes of mild intermittent jaundice due to predominantly unconjugated hyperbilirubinemia. Symptoms usually first appear during adolescence, when alterations in sex steroid concentrations alter bilirubin metabolism, leading to increased plasma bilirubin concentrations [<a href="#rid9">9</a>]. Other than intermittent episodes of mild jaundice, patients are typically asymptomatic, though some will have nonspecific complaints, such as malaise, abdominal discomfort, or fatigue, of uncertain relation to the elevated plasma bilirubin concentration [<a href="#rid15">15</a>].</p><p>The physical examination in a patient with Gilbert syndrome is often normal because bilirubin levels are often below the levels needed to result in jaundice. During an episode of jaundice, the examination will be notable for scleral icterus.</p><p class="headingAnchor" id="H7"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>Routine laboratory tests are usually normal in patients with Gilbert syndrome, except for unconjugated hyperbilirubinemia  (<a class="graphic graphic_table graphicRef80818" href="/d/graphic/80818.html" rel="external">table 1</a>). Serum bilirubin levels fluctuate; they are usually less than 4 mg/dL and can be normal. The conjugated bilirubin is typically less than 20 percent of the total bilirubin fraction. </p><p class="headingAnchor" id="H2878262759"><span class="h2">Exacerbating factors</span><span class="headingEndMark"> — </span>Certain associated pathologic conditions or physiologic events can increase the plasma bilirubin concentrations to higher values, but usually less than 6 mg/dL. </p><p>Episodes of jaundice in patients with Gilbert syndrome can be triggered by events that lead to increased bilirubin production, such as [<a href="#rid3">3,16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fasting</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolysis</p><p class="bulletIndent1"><span class="glyph">●</span>Intercurrent febrile illnesses</p><p class="bulletIndent1"><span class="glyph">●</span>Physical exertion</p><p class="bulletIndent1"><span class="glyph">●</span>Stress</p><p class="bulletIndent1"><span class="glyph">●</span>Menses </p><p></p><p>Reducing total daily caloric intake to 400 kcal results in a two- to threefold increase in the plasma bilirubin concentration within 48 hours [<a href="#rid17">17,18</a>]. A similar rise in bilirubin occurs in patients with Gilbert syndrome who receive a normocaloric diet without lipids [<a href="#rid19">19</a>]. The bilirubin concentration returns to baseline within 12 to 24 hours after resuming a normal diet. The cause of hyperbilirubinemia during fasting is probably multifactorial. Several causes have been hypothesized to contribute, including an increased bilirubin load due to the release of bilirubin contained within adipocytes, decreased conjugation due to depletion of UDP-glucuronic acid (which serves as a co-substrate in glucuronidation), and enhanced cycling of bilirubin by the enterohepatic circulation [<a href="#rid20">20-23</a>]. Intercurrent febrile illnesses, physical exertion, and stress probably cause hyperbilirubinemia by the same mechanisms as fasting [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H78566112"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H350920303"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Gilbert syndrome should be suspected in individuals with mild unconjugated hyperbilirubinemia possibly provoked by factors such as dehydration, fasting, intercurrent disease, menstruation, or overexertion, and no apparent liver disease or hemolysis. A presumptive diagnosis can be made in patients with the following features [<a href="#rid24">24-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unconjugated hyperbilirubinemia (&lt;4 mg/dL) on repeated testing</p><p class="bulletIndent1"><span class="glyph">●</span>A normal complete blood count, blood smear, and reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Normal plasma aminotransferases and alkaline phosphatase concentrations</p><p></p><p>The diagnosis is definitive in patients who continue to have normal laboratory studies (other than the elevation in plasma bilirubin) during the next 12 to 18 months. Genetic testing can confirm the diagnosis in settings where there is diagnostic confusion [<a href="#rid4">4</a>]. It is available at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=3578" target="_blank">some clinical laboratories</a>.</p><p class="bulletIndent1">There is no role for liver biopsy in the diagnosis of Gilbert syndrome. Histopathologically, the liver is normal except for nonspecific accumulation of lipofuscin pigment in the centrilobular zones [<a href="#rid28">28</a>]. Minor abnormalities may be seen by electron microscopy. </p><p></p><p>Provocative tests are not performed in clinical practice. Examples of provocative tests that can support the diagnosis of Gilbert syndrome include a rise in the plasma bilirubin concentration following a low lipid, 400 kcal diet or within three hours of administration of intravenous nicotinic acid [<a href="#rid21">21,29-31</a>]. </p><p class="headingAnchor" id="H3026659891"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of Gilbert syndrome includes disorders associated with an isolated increase in unconjugated bilirubin alone. The initial evaluation of a patient with isolated unconjugated hyperbilirubinemia includes an assessment for hemolytic anemia and discontinuation of medications (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a>) that impair hepatic uptake of bilirubin. (See  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a>.)</p><p>Patients with Gilbert syndrome may also have coexisting conditions that may cause higher levels of unconjugated hyperbilirubinemia (eg, Crigler-Najjar-type structural mutation, a disorder that causes hemolysis) [<a href="#rid32">32-34</a>]. However, these patients have higher levels of hyperbilirubinemia (&gt;4 mg/dL).</p><p>Complex clinical disorders such as hepatitis or cirrhosis can affect multiple processes, resulting in elevation of liver tests and the accumulation of both unconjugated and conjugated bilirubin. In these settings, the proportion of conjugated bilirubin in plasma increases. In contrast, the unconjugated fraction alone is increased in patients with Gilbert syndrome.</p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H3290217527"><span class="h2">Patient education and reassurance</span><span class="headingEndMark"> — </span>No specific therapy is required for patients with Gilbert syndrome. Patients should be educated about avoiding exacerbating conditions and an increased risk of toxicity with specific medications. As Gilbert syndrome is a hereditary condition with incomplete penetrance, patients should inform family members to prevent unnecessary diagnostic testing. (See <a class="local">'Genetics'</a> above.)</p><p class="headingAnchor" id="H1192189670"><span class="h2">Important considerations with medications</span><span class="headingEndMark"> — </span>Administration of corticosteroids, which increase hepatic uptake of bilirubin, or administration of hepatic enzyme inducers (such as <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a> and clofibrate), normalize plasma bilirubin concentrations within one to two weeks [<a href="#rid35">35-37</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications requiring bilirubin-UGT mediated glucuronidation</strong>  </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a><strong> toxicity</strong> – Gilbert syndrome is known to increase the risk of toxicity with irinotecan. The active metabolite of irinotecan, SN-38, is glucuronidated in the liver mainly by bilirubin-uridine diphosphoglucuronate-glucuronosyltransferase (UGT). The major dose-limiting toxicity is diarrhea, and in patients who inherit certain <em>UGT1A1</em> polymorphisms, reduced glucuronidation of SN-38 leads to an increased incidence of diarrhea and neutropenia, which may be severe [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/2503.html" rel="external">"Systemic therapy for nonoperable metastatic colorectal cancer: Selecting the initial therapeutic approach", section on 'Treatment-related toxicity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other medications</strong> – The effect of Gilbert syndrome on other drugs that require bilirubin-UGT-mediated hepatic glucuronidation is less clear. As an example, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a> and <a class="drug drug_general" data-topicid="10003" href="/d/drug information/10003.html" rel="external">tolbutamide</a> require bilirubin-UGT-mediated hepatic glucuronidation, but it is unclear if alterations in glucuronidation of these drugs has clinical significance, and avoiding these drugs in patients with Gilbert syndrome is not recommended [<a href="#rid40">40,41</a>]. Theoretically, diminished excretion of these drugs could potentially cause their accumulation and increase toxic effects. Studies based on intravenous administration of acetaminophen found reduced glucuronidation of the drug in subjects with Gilbert syndrome [<a href="#rid40">40</a>]. However, no such correlation was found after oral administration [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Isolated hyperbilirubinemia with drugs that inhibit bilirubin-UGT activity</strong> – Several medications can induce hyperbilirubinemia in patients with Gilbert syndrome by inhibiting bilirubin-UGT activity. Hyperbilirubinemia resolves rapidly once therapy is stopped, however, discontinuation of treatment is not necessary [<a href="#rid44">44</a>]. Examples include <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a>, an antiretroviral medication [<a href="#rid45">45</a>], <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> [<a href="#rid46">46</a>], <a class="drug drug_general" data-topicid="9524" href="/d/drug information/9524.html" rel="external">pazopanib</a>, <a class="drug drug_general" data-topicid="10305" href="/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid47">47,48</a>], and <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H78566772"><span class="h1">NATURAL HISTORY</span></p><p class="headingAnchor" id="H968251205"><span class="h2">Long-term complications</span><span class="headingEndMark"> — </span>Gilbert syndrome has been associated with an increased risk of cholelithiasis in adults and children [<a href="#rid50">50,51</a>]. Coinheritance of disorders that predispose to hemolysis, such as hereditary spherocytosis, thalassemia major, and sickle cell disease, may further increase that risk [<a href="#rid52">52-54</a>]. (See  <a class="medical medical_review" href="/d/html/3589.html" rel="external">"Hepatic manifestations of sickle cell disease", section on 'Cholelithiasis'</a> and  <a class="medical medical_review" href="/d/html/7116.html" rel="external">"Diagnosis of thalassemia (adults and children)", section on 'Jaundice and pigment gallstones'</a> and  <a class="medical medical_review" href="/d/html/7079.html" rel="external">"Hereditary spherocytosis", section on 'Pigment gallstones'</a>.)</p><p class="headingAnchor" id="H3302950121"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>Several studies have suggested that mildly increased serum bilirubin levels, such as those associated with Gilbert syndrome, may be beneficial because of the antioxidative, anti-inflammatory, and metabolic effects of bilirubin. Patients with Gilbert syndrome may have a lower incidence of atherosclerotic heart disease, lung and colon cancer [<a href="#rid3">3,40,42,55,56</a>]. </p><p>In patients with diabetes mellitus type 2, visceral fat and insulin resistance was inversely related to serum bilirubin levels [<a href="#rid57">57</a>]. The beneficial effect is not specific for the <em>UGT1A1*28</em> genotype but is related directly to serum bilirubin levels [<a href="#rid58">58</a>]. In one population-based cohort study, all all-cause mortality was markedly reduced in individuals with hyperbilirubinemia with Gilbert syndrome as compared with individuals without Gilbert syndrome [<a href="#rid59">59</a>].</p><p>A report of increased breast cancer risk in subjects with Gilbert syndrome [<a href="#rid60">60</a>] has not been confirmed in larger studies [<a href="#rid61">61</a>]. </p><p class="headingAnchor" id="H246000543"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116713.html" rel="external">"Society guideline links: Inherited liver disease"</a>.)</p><p class="headingAnchor" id="H88009076"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/17219.html" rel="external">"Patient education: Gilbert syndrome (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4571.html" rel="external">"Patient education: Gilbert syndrome (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Gilbert syndrome is the most common inherited disorder of bilirubin glucuronidation, with a prevalence of up to14 percent. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Gilbert syndrome is the result of a defect in the promotor of the gene that encodes the enzyme uridine diphosphoglucuronate-glucuronosyltransferase 1A1, which is responsible for the conjugation of bilirubin with glucuronic acid, converting bilirubin into a water-soluble form that is readily excreted in bile. (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – With the exception of intermittent episode of jaundice, most patients with Gilbert syndrome are asymptomatic and have normal physical examination findings. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory findings and exacerbating factors </strong>– Laboratory testing reveals unconjugated hyperbilirubinemia, with total bilirubin levels that are usually less than 4 mg/dL, though in the setting of exacerbating factors, the levels may be higher but are usually &lt;6 mg/dL. (See <a class="local">'Laboratory findings'</a> above and <a class="local">'Exacerbating factors'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– A presumptive diagnosis of Gilbert syndrome may be made in patients with the following features:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unconjugated hyperbilirubinemia (&lt;4 mg/dL) on repeated testing</p><p class="bulletIndent2"><span class="glyph">•</span>A normal complete blood count, blood smear, and reticulocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Normal plasma aminotransferases and alkaline phosphatase concentrations</p><p></p><p class="bulletIndent1">The diagnosis is definitive in patients who continue to have normal laboratory studies (other than the elevation in plasma bilirubin) during the next 12 to 18 months. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – No specific therapy is required for patients with Gilbert syndrome. Patients should be educated about avoiding exacerbating conditions and an increased risk of toxicity with specific medications. Patients should also inform family members to prevent unnecessary diagnostic testing. (See <a class="local">'Management'</a> above and <a class="local">'Important considerations with medications'</a> above and <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Natural history </strong>– Patients with Gilbert syndrome are at increased risk for gallstones, although the magnitude of this risk is unclear. Patients with Gilbert syndrome may have a lower risk of atherosclerotic heart disease, colon and lung cancer, and low mortality rates as compared with the general population. (See <a class="local">'Natural history'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Gilbert A, Lereboullet P. La cholamae simple familiale. Sem Med 1901; 21:241.</a></li><li><a class="nounderline abstract_t">Vítek L, Tiribelli C. Gilbert's syndrome revisited. J Hepatol 2023; 79:1049.</a></li><li><a class="nounderline abstract_t">Fretzayas A, Moustaki M, Liapi O, Karpathios T. Gilbert syndrome. Eur J Pediatr 2012; 171:11.</a></li><li><a class="nounderline abstract_t">Borlak J, Thum T, Landt O, et al. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects. Hepatology 2000; 32:792.</a></li><li><a class="nounderline abstract_t">Sieg A, Arab L, Schlierf G, et al. [Prevalence of Gilbert's syndrome in Germany]. Dtsch Med Wochenschr 1987; 112:1206.</a></li><li><a class="nounderline abstract_t">Monaghan G, Ryan M, Seddon R, et al. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578.</a></li><li><a class="nounderline abstract_t">Lampe JW, Bigler J, Horner NK, Potter JD. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9:341.</a></li><li><a class="nounderline abstract_t">Raijmakers MT, Jansen PL, Steegers EA, Peters WH. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 2000; 33:348.</a></li><li><a class="nounderline abstract_t">Muraca M, Fevery J. Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver. Gastroenterology 1984; 87:308.</a></li><li><a class="nounderline abstract_t">Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333:1171.</a></li><li><a class="nounderline abstract_t">Aono S, Adachi Y, Uyama E, et al. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet 1995; 345:958.</a></li><li><a class="nounderline abstract_t">Koiwai O, Nishizawa M, Hasada K, et al. Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase. Hum Mol Genet 1995; 4:1183.</a></li><li><a class="nounderline abstract_t">Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect. Gastroenterology 1997; 112:2099.</a></li><li><a class="nounderline abstract_t">Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet 2001; 38:244.</a></li><li><a class="nounderline abstract_t">Powell LW, Hemingway E, Billing BH, Sherlock S. Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families. N Engl J Med 1967; 277:1108.</a></li><li class="breakAll">Cobelli C, Ruggeri A, Toffolo G. BSP vs bilirubin kinetics in Gilbert's syndrome. In: Familial Hyperbilirubinemia, Okolicsanyi L (Ed), Wiley, New York 1981. p.121.</li><li><a class="nounderline abstract_t">Felsher BF, Rickard D, Redeker AG. The reciprocal relation between caloric intake and the degree of hyperbilirubinemia in Gilbert's syndrome. N Engl J Med 1970; 283:170.</a></li><li><a class="nounderline abstract_t">Barrett PV. Hyperbilirubinemia of fasting. JAMA 1971; 217:1349.</a></li><li><a class="nounderline abstract_t">Gollan JL, Bateman C, Billing BH. Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome. Gut 1976; 17:335.</a></li><li><a class="nounderline abstract_t">Cowan RE, Thompson RP, Kaye JP, Clark GM. The association between fasting hyperbilirubinaemia and serum non-esterified fatty acids in man. Clin Sci Mol Med 1977; 53:155.</a></li><li><a class="nounderline abstract_t">Felsher BF, Carpio NM, VanCouvering K. Effect of fasting and phenobarbital on hepatic UDP-glucuronic acid formation in the rat. J Lab Clin Med 1979; 93:414.</a></li><li><a class="nounderline abstract_t">Kotal P, Vítek L, Fevery J. Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility. Gastroenterology 1996; 111:217.</a></li><li><a class="nounderline abstract_t">Brink MA, Méndez-Sánchez N, Carey MC. Bilirubin cycles enterohepatically after ileal resection in the rat. Gastroenterology 1996; 110:1945.</a></li><li><a class="nounderline abstract_t">Roda A, Roda E, Sama C, et al. Serum primary bile acids in Gilbert's syndrome. Gastroenterology 1982; 82:77.</a></li><li><a class="nounderline abstract_t">Vierling JM, Berk PD, Hofmann AF, et al. Normal fasting-state levels of serum cholyl-conjugated bile acids in Gilbert's syndrome: an aid to the diagnosis. Hepatology 1982; 2:340.</a></li><li><a class="nounderline abstract_t">Douglas JG, Beckett GJ, Nimmo IA, et al. Bile salt measurements in Gilbert's syndrome. Eur J Clin Invest 1981; 11:421.</a></li><li><a class="nounderline abstract_t">Okolicsanyi L, Fevery J, Billing B, et al. How should mild, isolated unconjugated hyperbilirubinemia be investigated? Semin Liver Dis 1983; 3:36.</a></li><li><a class="nounderline abstract_t">SAGILD U, DALGAARD OZ, TYGSTRUP N. Constitutional hyperbilirubinemia with unconjugated bilirubin in the serum and lipochrome-like pigment granules in the liver. Ann Intern Med 1962; 56:308.</a></li><li><a class="nounderline abstract_t">Fromke VL, Miller D. Constitutional hepatic dysfunction (CHD; Gilbert's disease); a review with special reference to a characteristic increase and prolongation of the hyperbilirubinemic response to nicotinic acid. Medicine (Baltimore) 1972; 51:451.</a></li><li><a class="nounderline abstract_t">GYDELL K. Nicotinic acid induced hyperbilirubinemia and hypersideremia. I. Observations in hemolytic disease and allied conditions. Acta Med Scand 1959; 164:305.</a></li><li><a class="nounderline abstract_t">Gentile S, Tiribelli C, Persico M, et al. Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome. J Lab Clin Med 1986; 107:166.</a></li><li><a class="nounderline abstract_t">Ellis E, Wagner M, Lammert F, et al. Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J Hepatol 2006; 44:243.</a></li><li><a class="nounderline abstract_t">Powell LW, Billing BH, Williams HS. An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive diisopropylfluorophosphate and chromium. Australas Ann Med 1967; 16:221.</a></li><li><a class="nounderline abstract_t">Blueger AF, Krupnikova EZ, Sondore VY, Semushina EP. Study of the etiology and pathogenesis of low grade nonhemolytic unconjugated hyperbilirubinemia (Gilbert's disease). Acta Hepatogastroenterol (Stuttg) 1977; 24:140.</a></li><li><a class="nounderline abstract_t">Ohkubo H, Okuda K, Iida S. Effects of corticosteroids on bilirubin metabolism in patients with Gilbert's syndrome. Hepatology 1981; 1:168.</a></li><li><a class="nounderline abstract_t">Black M, Sherlock S. Treatment of Gilbert's syndrome with phenobarbitone. Lancet 1970; 1:1359.</a></li><li><a class="nounderline abstract_t">Kutz K, Kandler H, Gugler R, Fevery J. Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) 1984; 66:389.</a></li><li><a class="nounderline abstract_t">Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847.</a></li><li><a class="nounderline abstract_t">Burchell B, Soars M, Monaghan G, et al. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicol Lett 2000; 112-113:333.</a></li><li><a class="nounderline abstract_t">de Morais SM, Uetrecht JP, Wells PG. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 1992; 102:577.</a></li><li><a class="nounderline abstract_t">Carulli N, Ponz de Leon M, Mauro E, et al. Alteration of drug metabolism in Gilbert's syndrome. Gut 1976; 17:581.</a></li><li><a class="nounderline abstract_t">Ullrich D, Sieg A, Blume R, et al. Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome. Eur J Clin Invest 1987; 17:237.</a></li><li><a class="nounderline abstract_t">Rauchschwalbe SK, Zühlsdorf MT, Wensing G, Kuhlmann J. Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ther 2004; 42:73.</a></li><li class="breakAll">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD) 2012.</li><li><a class="nounderline abstract_t">Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44:1324.</a></li><li><a class="nounderline abstract_t">Deterding K, Grüngreiff K, Lankisch TO, et al. Gilbert's syndrome and antiviral therapy of hepatitis C. Ann Hepatol 2009; 8:246.</a></li><li><a class="nounderline abstract_t">Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010; 102:1371.</a></li><li><a class="nounderline abstract_t">Motzer RJ, Johnson T, Choueiri TK, et al. Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. Ann Oncol 2013; 24:2927.</a></li><li><a class="nounderline abstract_t">Simondsen KA, Kolesar JM. Lenalidomide-induced elevated bilirubin. J Oncol Pharm Pract 2012; 18:402.</a></li><li><a class="nounderline abstract_t">Bale G, Avanthi US, Padaki NR, et al. Incidence and Risk of Gallstone Disease in Gilbert's Syndrome Patients in Indian Population. J Clin Exp Hepatol 2018; 8:362.</a></li><li><a class="nounderline abstract_t">Tsezou A, Tzetis M, Giannatou E, et al. Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population. Genet Test Mol Biomarkers 2009; 13:143.</a></li><li><a class="nounderline abstract_t">del Giudice EM, Perrotta S, Nobili B, et al. Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis. Blood 1999; 94:2259.</a></li><li><a class="nounderline abstract_t">Origa R, Galanello R, Perseu L, et al. Cholelithiasis in thalassemia major. Eur J Haematol 2009; 82:22.</a></li><li><a class="nounderline abstract_t">Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005; 105:968.</a></li><li><a class="nounderline abstract_t">Akboga MK, Canpolat U, Sahinarslan A, et al. Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation. Atherosclerosis 2015; 240:110.</a></li><li><a class="nounderline abstract_t">Inoguchi T, Nohara Y, Nojiri C, Nakashima N. Association of serum bilirubin levels with risk of cancer development and total death. Sci Rep 2021; 11:13224.</a></li><li><a class="nounderline abstract_t">Liu J, Dong H, Zhang Y, et al. Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγ Levels. Sci Rep 2015; 5:9886.</a></li><li><a class="nounderline abstract_t">Gordon DM, Neifer KL, Hamoud AA, et al. Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptor α. J Biol Chem 2020; 295:9804.</a></li><li><a class="nounderline abstract_t">Horsfall LJ, Nazareth I, Pereira SP, Petersen I. Gilbert's syndrome and the risk of death: a population-based cohort study. J Gastroenterol Hepatol 2013; 28:1643.</a></li><li><a class="nounderline abstract_t">Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60:950.</a></li><li><a class="nounderline abstract_t">Guillemette C, De Vivo I, Hankinson SE, et al. Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels. Cancer Epidemiol Biomarkers Prev 2001; 10:711.</a></li></ol></div><div id="topicVersionRevision">Topic 3578 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : La cholamae simple familiale</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37390966" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Gilbert's syndrome revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160004" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gilbert syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11003624" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert's syndrome) in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3608845" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : [Prevalence of Gilbert's syndrome in Germany].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8596320" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10471066" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11019988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6428963" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565971" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7715297" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8528206" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gilbert's syndrome is caused by a heterozygous missense mutation in the gene for bilirubin UDP-glucuronosyltransferase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9178703" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Kernicterus in an adult who is heterozygous for Crigler-Najjar syndrome and homozygous for Gilbert-type genetic defect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11370628" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054997" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6054997" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome). A study of 42 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5424007" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The reciprocal relation between caloric intake and the degree of hyperbilirubinemia in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5109641" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hyperbilirubinemia of fasting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1278716" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of dietary composition on the unconjugated hyperbilirubinaemia of Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/891104" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The association between fasting hyperbilirubinaemia and serum non-esterified fatty acids in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/107254" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effect of fasting and phenobarbital on hepatic UDP-glucuronic acid formation in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698202" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fasting-related hyperbilirubinemia in rats: the effect of decreased intestinal motility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964422" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bilirubin cycles enterohepatically after ileal resection in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053338" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum primary bile acids in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7076117" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Normal fasting-state levels of serum cholyl-conjugated bile acids in Gilbert's syndrome: an aid to the diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6800816" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Bile salt measurements in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6340206" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : How should mild, isolated unconjugated hyperbilirubinemia be investigated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14496018" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Constitutional hyperbilirubinemia with unconjugated bilirubin in the serum and lipochrome-like pigment granules in the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4564417" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Constitutional hepatic dysfunction (CHD; Gilbert's disease); a review with special reference to a characteristic increase and prolongation of the hyperbilirubinemic response to nicotinic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13830555" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nicotinic acid induced hyperbilirubinemia and hypersideremia. I. Observations in hemolytic disease and allied conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3944496" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288819" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6056611" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : An assessment of red cell survival in idiopathic unconjugated hyperbilirubinaemia (Gilbert's syndrome) by the use of radioactive diisopropylfluorophosphate and chromium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/883461" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Study of the etiology and pathogenesis of low grade nonhemolytic unconjugated hyperbilirubinemia (Gilbert's disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7286896" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effects of corticosteroids on bilirubin metabolism in patients with Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4195058" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of Gilbert's syndrome with phenobarbitone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6697662" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466980" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720749" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732127" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/976795" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Alteration of drug metabolism in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3113968" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Normal pathways for glucuronidation, sulphation and oxidation of paracetamol in Gilbert's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180166" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15180166" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17058217" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841506" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gilbert's syndrome and antiviral therapy of hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20389299" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24107802" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22407059" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lenalidomide-induced elevated bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30563996" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Incidence and Risk of Gallstone Disease in Gilbert's Syndrome Patients in Indian Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19309288" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Gilbert syndrome as a predisposing factor for cholelithiasis risk in the Greek adult population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10498597" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Coinheritance of Gilbert syndrome increases the risk for developing gallstones in patients with hereditary spherocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19021734" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cholelithiasis in thalassemia major.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388579" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : UGT1A1 variation and gallstone formation in sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770689" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association of serum total bilirubin level with severity of coronary atherosclerosis is linked to systemic inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34168201" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Association of serum bilirubin levels with risk of cancer development and total death.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26017184" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bilirubin Increases Insulin Sensitivity by Regulating Cholesterol Metabolism, Adipokines and PPARγLevels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32404366" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bilirubin remodels murine white adipose tissue by reshaping mitochondrial activity and the coregulator profile of peroxisome proliferator-activated receptorα.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701650" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gilbert's syndrome and the risk of death: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706110" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401924" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
